Enriching access to multimodal data insights with COTA Connect

Today, COTA is introducing COTA Connect: a powerful new capability to link data with a variety of different supplemental data sources, including linking COTA’s robust real-world clinical data to claims, imaging, socioeconomic data, and more.

We’re excited about COTA Connect – another step toward making it easier and more cost-effective to understand the precise mix of preventative care and treatments so that patients can live longer, healthier, and productive lives. 
-Miruna Sasu at Datavant’s Future of Health Data Summit

A patient’s journey through the healthcare system is never linear, especially when cancer care is involved. Each individual is likely to have multiple provider types involved in their care, often spread across different health systems, which can make it challenging to assemble a complete, accurate, longitudinal portrait of all their interactions with care providers and other entities.
Yet in order to improve care and develop new therapies, both clinical trial sponsors and clinicians urgently require access to comprehensive insights about how patients are interacting with specific treatments, tests, and drugs.
“We know the patient journey is very complex and there are many layers to how cancer care plays out in real-world scenarios,” said Miruna Sasu, CEO of COTA. “Life science companies and provider organizations have been searching for better ways to aggregate larger multimodal real-world datasets to uncover existing patterns in care and explore opportunities to improve. COTA Connect provides the visibility and insight necessary to make more informed decisions based on richer, broader, and deeper data.”
COTA will provide the tokens that allow linkage to a claims data source, creating a more comprehensive view of patients’ care. This increases granularity of understanding around individuals and populations of interest. COTA can also provide analytical services to analyze the merged dataset and answer relevant research questions.
The result is the ability to dive deeply into the data to support work by a variety of key teams, including clinical development, HEOR, safety, medical affairs, and market access.
Datasets enriched with claims data can help life sciences and clinical teams with a range of crucial tasks, including:
  • Analyzing costs and resource utilization: Combined data can reveal relationships between treatment selection, resource utilization, costs, and health outcomes to support quality initiatives, aid research, and develop improved standards of care.
  • Understanding relationships between cancer and other healthcare issues: People with cancer often have other comorbidities that influence spending, utilization, and quality of life. The ability to explore non-oncology data elements in conjunction with oncology events can help coordinate care and highlight unintended side effects of therapies.
  • Capturing additional detail for a comprehensive journey: Claims data contains a wealth of information about specialty care, referrals, prescriptions, and ED utilization that may enhance understanding of how cancer impacts costs, outcomes, and risk scores. As value-based care becomes more important in oncology, so will the ability to have a full understanding of a patient’s clinical status and utilization across the entire care continuum.

“COTA Connect is a high-value supplement to our flagship Focus and Vantage offerings,” said Sandy Leonard from COTA. “We’re excited to provide these critical additional features to make it easier and more cost-effective to access real-world data that can have a measurable impact on the work of life science companies and clinical care providers.”